Connect with us
The company said it was seeking new sources of capital to support its research and development. New York-based biotech firm Bright Minds Biosciences Inc. (Nasdaq: DRUG)...
New York-based biotech firm Seelos Therapeutics Inc. (Nasdaq: SEEL) reported a net income of $1.7 million for the second quarter of the year, but the company...
Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) released its second-quarter financial results for the period ending June 30, 2024. Filament Health remains in a drug discovery phase...
Neuronetics, Inc. (NASDAQ: STIM) is buying Greenbrook TMS Inc. (OTCMKTS: GBNHF) in an all-stock transaction. The combined company will continue to operate as Neuronetics, Inc., and...
Alto Neuroscience, Inc. (NYSE: ANRO) delivered its financial results for the second quarter ending June 30, 2024, and updated investors on its ALTO-100 drug. The company...
The company aims to have a pre-Investigational New Drug meeting with the FDA for EB-003 in early 2025. Enveric Biosciences (NASDAQ: ENVB) reported a narrower second-quarter...
MineMed said it is on track for Phase 3 studies later this year. Mind Medicine Inc. (MindMed) Inc. (NASDAQ: MNMD) announced its financial results for the...
Atai Life Sciences (NASDAQ: ATAI) announced its second-quarter 2024 financial results and provided corporate updates. The company has little revenue to report as it is in...
The U.S. Food and Drug Administration’s decision to reject MDMA-assisted therapy for post-traumatic stress disorder sent ripples through the psychedelic industry. The FDA issued a complete...
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) told investors it was changing its name to Quantum BioPharma Ltd. and consolidating shares. The company didn’t give a...
